Evaluating Enoxaparin Dosing Strategies for Venous Thromboembolism Prophylaxis in Bariatric Surgery PatientsHigher enoxaparin doses do not change outcomes for bariatric surgery

Obesity surgery Published August 1, 2026 Study authors: Albashier Mahmoud, Moqbel Ibrahim, Saleh Ahmad Omar, Mohammed Rawan Kamal, Mahadin Mohammad, Ezz Moh… PubMed ↗ DOI ↗ Editorial oversight: Dr. Amelia Tan, PhD · Internal Medicine & Chronic Disease

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway

Higher enoxaparin doses improve anti-factor Xa levels but do not result in superior clinical outcomes for bariatric patients.

Clinical management of venous thromboembolism (VTE) in bariatric surgery patients presents a unique challenge due to the high risk profile associated with obesity. This meta-analysis evaluated the efficacy and safety of two different enoxaparin dosages—40 mg versus 60 mg—to determine if higher pharmacokinetic levels correlate with improved clinical outcomes or reduced complication rates.

The primary objective was to assess the achievement of prophylactic anti-factor Xa levels between the two cohorts. The data revealed that patients receiving the 60 mg dose achieved significantly higher mean anti-factor Xa levels compared to those receiving 40 mg (MD -0.08 IU/mL; 95% CI -0.13 to -0.03). This suggests a clear pharmacokinetic distinction between the two dosing regimens.

Further analysis of specific thresholds showed that the 40 mg group had higher rates of sub-prophylactic anti-factor Xa levels (RR 1.35; 95% CI 1.03-1.77). Conversely, the 60 mg group demonstrated lower rates of supra-prophylactic levels compared to the 40 mg group (RR 0.25; 95% CI 0.09-0.70). These findings indicate that the 60 mg dose provides a more consistent pharmacological profile within the target therapeutic window.

Despite these differences in pharmacokinetic markers, the clinical outcomes did not vary significantly between the two groups. There were no statistically significant differences observed in the incidence of venous thromboembolism (VTE), deep vein thrombosis (DVT), or pulmonary embolism (PE). Furthermore, neither group showed significant variations in bleeding events, mortality rates, or overall surgical complications.

Secondary metrics such as operative duration and transfusion requirements also remained consistent across both cohorts. While the 60 mg dose successfully achieved higher anti-factor Xa levels, this pharmacological advantage did not translate into a measurable reduction in clinical risks or improvements in patient safety during the perioperative period.

One notable observation was that while overall target attainment showed no significant difference between groups, the once-daily 40 mg dose was associated with lower rates of reaching target anti-Xa levels compared to the 60 mg dose. This highlights a specific pharmacokinetic gap even when clinical outcomes remain stable.

In conclusion, while higher enoxaparin doses provide more consistent and robust anti-factor Xa profiles in bariatric patients, they do not appear to offer superior protection against VTE or reduce bleeding risks compared to lower doses. Clinicians may choose the dose that best fits institutional protocols, as both 40 mg and 60 mg demonstrate comparable safety and efficacy profiles in this specific population.

How this fits prior evidence

How this fits prior evidence This meta-analysis addresses a gap in the management of patients undergoing bariatric surgery by evaluating enoxaparin dosing. While previous coverage noted that whey protein may mitigate body weight loss after bariatric surgery and that paraumbilical hernias can cause gastric outlet obstruction in patients with severe obesity, this study specifically focuses on the pharmacological management of VTE risk during the surgical procedure.

For people with obesity planning to undergo bariatric surgery, there is a major concern about safety during and after the procedure. Because of their size, these patients are at a higher risk for blood clots, which can be dangerous. To prevent these clots, doctors often use a medication called enoxaparin. This medicine helps keep the blood flowing correctly while the patient recovers from surgery.

Researchers looked at data from 1,276 patients to see if giving a higher dose of this medicine—specifically 60 mg instead of 40 mg—made a difference in how well it worked. They measured something called anti-factor Xa levels. This is a lab test used to check if the amount of medicine in the body is enough to prevent clots but not so much that it causes dangerous bleeding.

The results showed a clear difference in the lab numbers, but not in the actual health outcomes for the patients. The 60 mg dose resulted in higher anti-factor Xa levels than the 40 mg dose. However, when looking at the real-world results, there was no significant difference between the two doses. Patients receiving either amount of medication had similar rates of blood clots, bleeding incidents, and overall complications. They also had similar survival rates and did not differ in how long their surgeries took or how much blood they needed during the operation.

It is important to keep this finding in perspective. While the higher dose did change the lab markers, those changes did not translate into better clinical results for the patients. This means that while the 60 mg dose provides a different level of medicine in the bloodstream, it does not appear to offer extra protection against clots or reduce the risk of bleeding compared to the 40 mg dose. For patients right now, this means that the choice between these two specific doses may not change their immediate safety profile. Because both doses performed similarly regarding major complications and blood clots, doctors can continue to use established protocols for weight loss surgery. This study highlights that while lab levels are helpful for monitoring, they do not always predict a different outcome for the patient's health.

What this means for you:

Higher doses of enoxaparin improved lab markers but did not change safety or outcomes for bariatric patients.

Study Details

Study typeMeta analysis

Sample sizen = 1,276

EvidenceLevel 1

PublishedJul 2026

PMID42268537

View Original Abstract ↓

BACKGROUND: Patients undergoing bariatric surgery face an elevated risk of venous thromboembolism (VTE), primarily due to obesity-related hypercoagulability and changes in the pharmacokinetics of anticoagulants. The standard prophylactic dosing of enoxaparin may not be adequate for this group, leading to the consideration of higher or BMI-adjusted dosing regimens. Nevertheless, the comparative efficacy and safety of standard-dose versus higher-dose enoxaparin in the context of bariatric surgery remain unclear. METHODS: A systematic review and meta-analysis were performed following the PRISMA 2020 guidelines. Searches were conducted in PubMed, Embase, Scopus, Web of Science, and the Cochrane Library from their inception through September 30, 2025. The review included randomized controlled trials and cohort studies comparing enoxaparin 40 mg with 60 mg for postoperative venous thromboembolism (VTE) prophylaxis in bariatric surgery. Studies utilizing fixed-dose or BMI-tiered dosing strategies were considered eligible. The primary outcome assessed was the achievement of prophylactic anti-factor Xa levels. Secondary outcomes comprised mean anti-factor Xa levels, sub- and supra-prophylactic anti-factor Xa levels, VTE occurrence, bleeding incidents, mortality rates, overall complications, operative duration, and transfusion requirements. Random-effects meta-analyses were conducted. RESULTS: Ten studies encompassing 1,276 patients (727 receiving 40 mg and 549 receiving 60 mg) were included. Enoxaparin 40 mg was associated with significantly lower mean anti-factor Xa levels compared with 60 mg (MD - 0.08 IU/mL; 95% CI - 0.13 to - 0.03). Patients receiving 40 mg had higher rates of sub-prophylactic anti-Xa levels (RR 1.35; 95% CI 1.03-1.77), whereas 60 mg was associated with increased supra-prophylactic levels (RR 0.25; 95% CI 0.09-0.70). Overall achievement of target prophylactic anti-Xa levels did not differ between doses, although once-daily 40 mg dosing was associated with reduced target attainment compared with once-daily 60 mg. No significant differences were observed in VTE, deep vein thrombosis, pulmonary embolism, bleeding, mortality, overall complications, operative duration, or transfusion requirements. CONCLUSIONS: Although higher enoxaparin doses improved anti-factor Xa levels, this did not translate into reductions in venous thromboembolism, bleeding, or mortality, underscoring the disconnect between pharmacokinetic markers and clinical outcomes in bariatric surgery patients. REGISTRATION: PROSPERO CRDXXXXXXXXXXX.

Evaluating Enoxaparin Dosing Strategies for Venous Thromboembolism Prophylaxis in Bariatric Surgery PatientsHigher enoxaparin doses do not change outcomes for bariatric surgery

How this fits prior evidence

Study Details

AI-OCT reports reduced false-positive DME referral rates from 69.1% to 24.1%

AI technology reduces unnecessary referrals for diabetic macular edema

Clinical research that matters. Delivered to your inbox.

Evaluating Enoxaparin Dosing Strategies for Venous Thromboembolism Prophylaxis in Bariatric Surgery PatientsHigher enoxaparin doses do not change outcomes for bariatric surgery

How this fits prior evidence

More on enoxaparin

Study Details

AI-OCT reports reduced false-positive DME referral rates from 69.1% to 24.1%

AI technology reduces unnecessary referrals for diabetic macular edema

Clinical research that matters. Delivered to your inbox.

Related in Diabetes & Endocrinology

From Other Specialties